Oxford BioMedica PLC (LSE:OXB)

£ 3.12 -0.03 (-0.95%) Market Cap: 328.44 Mil Enterprise Value: 336.18 Mil PE Ratio: 0 PB Ratio: 4.08 GF Score: 71/100

Oxford Biomedica PLC oxford Biomedica to host webinar showcasing the TetraVectaTM system Transcript
Oct 02, 2023
Half Year 2023 Oxford Biomedica PLC Earnings Call Transcript
Sep 20, 2023

£2.69 (+11.39%)

Earnings
Full Year 2022 Oxford Biomedica PLC Earnings Call Transcript
Apr 25, 2023

£4.53 (+0.67%)

Earnings
Oxford Biomedica PLC at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Half Year 2022 Oxford BioMedica PLC Earnings Call Transcript
Sep 15, 2022

£4.4 (-3.93%)

Earnings
Full Year 2021 Oxford BioMedica PLC Earnings Call Transcript
Apr 20, 2022

£5.45 (-14.71%)

Earnings
Half Year 2021 Oxford BioMedica PLC Earnings Call Transcript
Sep 22, 2021

£16.34 (+10.55%)

Earnings
Full Year 2020 Oxford BioMedica PLC Earnings Call Transcript
Apr 15, 2021

£10.42 (+0.19%)

Earnings
Half Year 2020 Oxford BioMedica PLC Earnings Call Transcript
Sep 17, 2020

£8.47 (+1.44%)

Earnings
Oxford BioMedica PLC Annual Shareholders Meeting Transcript
Jun 23, 2020
Full Year 2019 Oxford BioMedica PLC Earnings Call Transcript
May 06, 2020

£7.07 (-2.75%)

Earnings
Half Year 2019 Oxford BioMedica PLC Earnings Call Transcript
Sep 04, 2019

£6.4 (+0.16%)

Earnings
Full Year 2018 Oxford BioMedica PLC Earnings Call Transcript
Mar 14, 2019

£6.5 (-2.26%)

Earnings

Full Year 2020 Oxford BioMedica PLC Earnings Call Transcript

Apr 15, 2021 / 12:00PM GMT

Release Date Price: £10.42 (+0.19%)

Transcript

Operator

Good day, ladies and gentlemen, and welcome to the Oxford Biomedica's Preliminary Results 2020 Briefing. (Operator Instructions)

I will now hand over to Catherine Isted to open the presentation. Please go ahead.

Catherine Isted

Oxford Biomedica plc - Head of Corporate Development & IR

Good afternoon, ladies and gentlemen. Welcome to Oxford Biomedica's full year results conference call for the year ending the 31st of December 2020. We are delighted today to talk through what hopefully, you will agree, is a very strong set of results. This is a year that the company has thrived in the most uncertain of backdrops and really shown it through highlighting to the world its global leading capabilities. We say we're a lifesaving cell and gene therapy company, and this has never been more true than the year that we've just had.

To discuss the year in more detail, I would like to introduce our presenters on the call today: Our CEO, John Dawson; our CFO, Stuart Paynter; and our Chief Scientific Officer, Kyri Mitrophanous.

With that, I'd

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.